IL2 and primary cutaneous T-cell non-Hodgkin lymphoma: Denileukin diftitox (Ontak®) is the first FDA-approved immunotoxin containing IL-2 and a truncated form of diphtheria toxin (DAB389) that is used for the treatment of recurrent cutaneous T-cell lymphoma (CTCL) [166].